96 completed, 28 terminated, 26 recruiting, 15 active not recruiting. 204 Phase 2, 21 Phase 1, 12 Phase 3.
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 52 | 2026-12-01 | 2026-10-20 |
| A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis AGMB-447, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | Agomab Spain S.L.U. | 120 | 2026-11-30 | 2026-10-07 |
| A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis HB0056, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 75 | 2026-11-01 | 2026-11-02 |
| Study of ORJ-001 for the Treatment of IPF ORJ-001, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | Oorja Bio, Inc. | 95 | 2026-10-01 | 2026-10-15 |
| Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3 - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 175 | 2026-08-25 | 2026-07-27 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis CHF10067, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | Chiesi Farmaceutici S.p.A. | 240 | 2026-07-08 | 2026-10-16 |
| A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis SYH2059 Tablets, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | InnovStone Therapeutics Limited | 156 | 2026-06-30 | 2026-05-20 |
| A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | AstraZeneca | 359 | 2026-06-11 | 2026-10-29 |
| Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Nintedanib Dry Powder Inhalation, Placebo - Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Mannkind Corporation | 153 | 2026-05-15 | 2026-09-14 |
| Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis [68Ga]CBP8, Gadoterate Meglumine - Interstitial Lung Disease, Pulmonary Fibrosis | Phase 2 | Recruiting | Peter Caravan | 15 | 2026-05-14 | 2026-07-14 |
| Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) Nintedanib,Dextromethorphan, Nintedanib,Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 60 | 2026-05-12 | 2026-05-13 |
| Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis BC006, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Dragonboat Biopharmaceutical Company Limited | 96 | 2026-04-27 | 2026-05-13 |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF AP02, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Avalyn Pharma Inc. | 160 | 2026-03-10 | 2026-10-15 |
| A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood BI 1015550, Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Boehringer Ingelheim | 20 | 2026-03-05 | 2026-08-21 |
| A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis LTI-03, Dry Powder Inhaler, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Rein Therapeutics | 120 | 2026-02-02 | 2026-11-02 |
| Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis ABBV-142, Placebo for ABBV-142 - Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | AbbVie | 165 | 2026-01-23 | 2026-09-03 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis PIPE-791 Dose A, PIPE-791 Dose B, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | Contineum Therapeutics | 324 | 2026-01-08 | 2026-11-02 |
| Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases Injection of 68Ga-NI-FAPI - Tumor, Cardiovascular Diseases | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-12-17 | 2026-03-11 |
| Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis FAPI tracer, PET/MRI - Fibrosis Lung | Phase 2 | Recruiting | University of Wisconsin, Madison | 50 | 2025-11-19 | 2026-10-01 |
Showing 20 of 204. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (152) · Lung Diseases, Interstitial (28) · Fibrosis (15) · Lung Diseases (12) · Hypertension, Pulmonary (11) · Cough (8) · Idiopathic Interstitial Pneumonias (8) · COVID-19 (7) · Respiratory Tract Diseases (7) · Scleroderma, Systemic (6) · Pulmonary Arterial Hypertension (4) · Sarcoidosis (4) · Scleroderma, Diffuse (4) · Alveolitis, Extrinsic Allergic (3)
Respiratory Tract Diseases (197) · Lung Diseases (192) · Lung Diseases, Interstitial (176) · Pathological Conditions, Signs and Symptoms (100) · Pathologic Processes (90) · Fibrosis (75) · Cardiovascular Diseases (15) · Vascular Diseases (14) · Immune System Diseases (13) · Skin and Connective Tissue Diseases (13) · Skin Diseases (12) · Hypertension (11) · Hemic and Lymphatic Diseases (10) · Infections (10)
pirfenidone (14) · nintedanib (6) · Rituximab (5) · Sildenafil Citrate (4) · Danazol (3) · Prednisone (3) · Standard of Care (3) · Therapeutics (3) · treprostinil (3) · Acetylcysteine (2) · BI 1015550 (2) · Bosentan (2) · Cyclophosphamide (2) · Formoterol Fumarate (2) · Gefapixant (2)
Boehringer Ingelheim (9) · Actelion (5) · Hoffmann-La Roche (5) · Novartis Pharmaceuticals (5) · National Heart, Lung, and Blood Institute (NHLBI) (4) · Pliant Therapeutics, Inc. (4) · Avalyn Pharma Inc. (3) · Biogen (3) · Haisco Pharmaceutical Group Co., Ltd. (3) · University of Alabama at Birmingham (3) · Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · Bellerophon (2) · Blade Therapeutics (2)
United States (114) · United Kingdom (53) · Australia (43) · Canada (43) · Germany (40) · Italy (36) · Spain (35) · France (33) · South Korea (28) · China (26) · Belgium (24) · Argentina (22) · Poland (22) · Netherlands (20) · Greece (19)
Sydney Montesi, MD (3) · Lisa Lancaster, M.D. (2) · Rajan Saggar, MD (2) · Steven R Duncan, MD (2) · Toby Maher, MD (2)
PMID 26083430, PMID 28993537, PMID 38509495, PMID 40355288, PMID 10415784, PMID 12563677, PMID 14719037, PMID 15663512, PMID 16883006, PMID 17181919, PMID 17356110, PMID 17585107, PMID 17675522, PMID 17901413, PMID 18097874, PMID 18669816, PMID 19397687, PMID 19453649, PMID 19679600, PMID 19998041, PMID 20007927, PMID 20012639, PMID 20126467, PMID 20506355, PMID 20739168, PMID 21131395, PMID 21373184, PMID 21992121, PMID 22028728, PMID 22379151, PMID 22545014, PMID 22731679, PMID 23262513, PMID 23682110, PMID 23872052, PMID 24431095, PMID 24628285, PMID 25504994, PMID 26493793, PMID 26496265, PMID 26867177, PMID 26965296, PMID 27192671, PMID 28388260, PMID 28584818, PMID 28619061, PMID 28787186, PMID 29100885, PMID 29792287, PMID 29800034
2023 (6), 2017 (4), 2014 (3), 2015 (2), 2018 (2), 2019 (2), 2025 (2), 2009 (1), 2016 (1), 272201800011C-P00005-9999-1 (1), P50HL056402 (1), P50HL067665 (1), R01HL171240 (1), U01HL105371 (1), U01HL133232 (1)